The phase II trial INSIGHT investigated antitumor activity of the association of tepotinib plus gefitinib versus standard platinum-doublet chemotherapy in patients with EGFR-mutant, T790M-negative NSCLC with MET overexpression or MET amplification. The gene discussed is MET; the disease is non-small cell lung carcinoma.